19th Ave New York, NY 95822, USA
Join Now

Grup de Proteòmica

Portfolio Item Grup de Proteòmica
TECNOLOGIES TRANSVERSALS

El nostre grup exerceix com a plataforma tecnològica central. Proporcionem metodologies proteòmiques d’avantguarda als investigadors del VHIO i incorporem els nous avenços en aquest camp per oferir les darreres estratègies i tecnologies.

Fem servir estratègies proteòmiques d’espectrometria de masses per al cribratge i la validació de biomarcadors per al diagnòstic del càncer, els tractaments de precisió i el seguiment més estret de la malaltia.

Una de les nostres línies de recerca se centra en el desenvolupament d’assajos d’espectrometria de masses per analitzar biomarcadors en mostres clíniques. Hem desenvolupat assaigs d’immunoespectrometria amb més selectivitat i precisió a l’anàlisi de proteïnes biomarcadores de baixa abundància en mostres de plasma o LCR.

Hem aplicat mètodes d’anàlisi proteòmica a la caracterització proteòmica i fosfoproteòmica de models de xenoempelts derivats de pacients (PDX) de càncer colorectal (CCR). Els PDX constitueixen una plataforma ideal per a la caracterització molecular proteòmica del CCR. Com a complement de la classificació genòmica, explorem la idoneïtat d’aquesta caracterització com a eina per a la classificació de subtipus tumorals.

Hem posat a punt metodologies d’anàlisi per espectrometria de masses de fàrmacs en mostres biològiques per estudiar-ne la farmacocinètica i la biodisponibilitat en models murins. A més, hem aplicat l’anàlisi proteòmica a la descripció dels interactors proteïna-proteïna i de les interaccions proteïna-fàrmac.

Francesc Canals
Cap de grup
Biosketch
Josep Villanueva
Cap de grup
Biosketch

Líneas de investigación

  • Com a instal·lació central, prestem serveis de tècniques proteòmiques a altres grups de recerca.
  • Duem a terme el cribratge proteòmic de nous biomarcadors per ajudar a desenvolupar teràpies contra el càncer.
  • Desenvolupem assaigs basats en l’espectrometria de masses per analitzar biomarcadors en mostres clíniques.
  • Contribuïm al mapeig del proteoma del cromosoma 16 com a part del projecte Proteoma humà.

Figura: La proteòmica en la recerca preclínica i translacional. El nostre laboratori ofereix anàlisis basades en espectrometria de masses de mostres de plasma, teixits o FFPE per: A) fer el seguiment de petits fàrmacs al plasma o als teixits d’animals model per a la caracterització farmacocinètica. B) elaborar el perfil del proteoma total i del fosfoproteoma dels models tumorals PDX per explorar les vies implicades en la resposta terapèutica. C) analitzar l’LCMS dirigit i D) analitzar la immunoespectrometria de masses per mesurar els nivells de biomarcadors en mostres clíniques per a l’estratificació de pacients o el seguiment del tractament.

Equip

Cap de grup
Francesc Canals
Post-Doctoral Fellows
Mireia Pujals
Joan Navarro
Graduate Students
Paula Carrillo
José Ángel Robles
Carla Mayans
Technicians
Marina Corominas
Luna Martín

Publicacions

Publicacions científiques més rellevants

  • McGrail K, Granado-Martínez P, Esteve-Puig R, García-Ortega S, Ding Y, Sánchez-Redondo S, Ferrer B, Hernandez-Losa J, Canals F, Manzano A, Navarro-Sabaté A, Bartrons R, Yanes O, Pérez-Alea M, Muñoz-Couselo E, Garcia-Patos V, Recio JA. BRAF activation by metabolic stress promotes glycolysis sensitizing NRASQ61-mutated melanomas to targeted therapy. Nat Commun. 2022 Nov 19;13(1):7113.
  • Juliachs M, Pujals M, Bellio C, Meo-Evoli N, Duran JM, Zamora E, Parés M, Suñol A, Méndez O, Sánchez-Pla A, Canals F, Saura C, Villanueva J. Circulating SOD2 Is a Candidate Response Biomarker for Neoadjuvant Therapy in Breast Cancer. Cancers (Basel). 2022 Aug 10;14(16):3858.
  • Bellio C, Emperador M, Castellano P, Gris-Oliver A, Canals F, Sánchez-Pla A, Zamora E, Arribas J, Saura C, Serra V, Tabernero J, Littlefield BA, Villanueva J. GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells. Cancers (Basel). 2022 May 23;14(10):2562.
  • Colomé N, Abian J, Aloria K, Arizmendi JM, Barceló-Batllori S, Braga-Lagache S, Burlet-Schiltz O, Carrascal M, Casal JI, Chicano-Gálvez E, Chiva C, Clemente LF, Elortza F, Estanyol JM, Fernandez-Irigoyen J, Fernández-Puente P, Fidalgo MJ, Froment C, Fuentes M, Fuentes-Almagro C, Gay M, Hainard A, Heller M, Hernández ML, Ibarrola N, Iloro I, Kieselbach T, Lario A, Locard-Paulet M, Marina-Ramírez A, Martín L, Morato-López E, Muñoz J, Navajas R, Odena MA, Odriozola L, de Oliveira E, Paradela A, Pasquarello C, de Los Rios V, Ruiz-Romero C, Sabidó E, Sánchez Del Pino M, Sancho J, Santamaría E, Schaeffer-Reiss C, Schneider J, de la Torre C, Valero ML, Vilaseca M, Wu S, Wu L, Ximénez de Embún P, Canals F, Corrales FJ; ProteoRed-ISCIII; EuPA. Multi-laboratory experiment PME11 for the standardization of phosphoproteome analysis. J Proteomics. 2022 Jan 16;251:104409.
  • Ramiro L, García-Berrocoso T, Briansó F, Goicoechea L, Simats A, Llombart V, Gonzalo R, Hainard A, Martínez-Saez E, Canals F, Sanchez JC, Sánchez-Pla A, Montaner J. Integrative Multi-omics Analysis to Characterize Human Brain Ischemia. Mol Neurobiol. 2021 Aug;58(8):4107-4121.
  • Colomé N, Abian J, Aloria K, Arizmendi JM, Barceló-Batllori S, Braga-Lagache S, Burlet-Schiltz O, Carrascal M, Casal JI, Chicano-Gálvez E, Chiva C, Clemente LF, Elortza F, Estanyol JM, Fernandez-Irigoyen J, Fernández-Puente P, Fidalgo MJ, Froment C, Fuentes M, Fuentes-Almagro C, Gay M, Hainard A, Heller M, Hernández ML, Ibarrola N, Iloro I, Kieselbach T, Lario A, Locard-Paulet M, Marina-Ramírez A, Martín L, Morato-López E, Muñoz J, Navajas R, Odena MA, Odriozola L, de Oliveira E, Paradela A, Pasquarello C, de Los Rios V, Ruiz-Romero C, Sabidó E, Sánchez Del Pino M, Sancho J, Santamaría E, Schaeffer-Reiss C, Schneider J, de la Torre C, Valero ML, Vilaseca M, Wu S, Wu L, Ximénez de Embún P, Canals F, Corrales FJ; ProteoRed-ISCIII; EuPA. Multi-laboratory experiment PME11 for the standardization of phosphoproteome analysis. J Proteomics. 2022 Jan 16;251:104409. Epub 2021 Nov 7.
  • Simats A, Ramiro L, García-Berrocoso T, Briansó F, Gonzalo R, Martín L, Sabé A, Gill N, Penalba A, Colome N, Sánchez A, Canals F, Bustamante A, Rosell A, Montaner J. A mouse brain-based multi-omics integrative approach reveals potential blood biomarkers for ischemic stroke. Mol Cell Proteomics. 2020 Dec;19(12):1921-1935.
  • Vitali M , Casals E , Canals F , Colomé N, Puntes V. Simple spectroscopic determination of the hard protein corona composition in AuNPs: albumin at 75. 2020 Aug 7;12(29):15832-15844.
  • Granado-Martínez P, Garcia-Ortega S, González-Sánchez E, McGrail K, Selgas R, Grueso J, Gil R, Naldaiz-Gastesi N, Rhodes AC, Hernandez-Losa J, Ferrer B, Canals F, Villanueva J, Méndez O, Espinosa-Gil S, Lizcano JM, Muñoz-Couselo E, García-Patos V, Recio JA. STK11 (LKB1) missense somatic mutant isoforms promote tumor growth, motility and inflammation. Commun Biol. 2020 Jul 9;3(1):366.
  • Marinelli P, Navarro S, Baño-Polo M, Morel B, Graña-Montes R, Sabe A, Canals F, Fernandez MR, Conejero-Lara F, Ventura S. Global Protein Stabilization Does Not Suffice to Prevent Amyloid Fibril Formation. ACS Chem Biol. 2018 Aug 17, 13(8):2094-2105.
  • Simats A, García-Berrocoso T, Penalba A, Giralt D, Llovera G, Jiang Y, Ramiro L, Bustamante A, Martinez-Saez E, Canals F, Wang X, Liesz A, Rosell A, Montaner J. CCL23: A new CC chemokine involved in human brain damage. J Intern Med. 2018 May; 283(5):461-475.
  • García-Berrocoso T, Llombart V, Colàs-Campàs L, Hainard A, Licker V, Penalba A, Ramiro L, Simats A, Bustamante A, Martínez-Saez E, Canals F, Sanchez JC, Montaner J. Single Cell Immuno-laser Microdissection Coupled to Label-free Proteomics to Reveal the Proteotypes of Human Brain Cells After Ischemia. Mol Cell Proteomics. 2018 Jan;17(1):175-189.
  • García-Berrocoso T, Llombart V, Colàs-Campàs L, Hainard A, Licker V, Penalba A, Ramiro L, Simats A, Bustamante A, Martínez-Saez E, Canals F, Sanchez JC, Montaner J. Single Cell Immuno-laser Microdissection Coupled to Label-free Proteomics to Reveal the Proteotypes of Human Brain Cells After Ischemia. Mol Cell Proteomics. 2017 Nov 13. [Epub ahead of print]
  • Mateo F, Arenas EJ, Aguilar H, Serra-Musach J, de Garibay GR, Boni J, Maicas M, Du S, Iorio F, Herranz-Ors C, Islam A, Prado X, Llorente A, Petit A, Vidal A, Català I, Soler T, Venturas G, Rojo-Sebastian A, Serra H, Cuadras D, Blanco I, Lozano J, Canals F, Sieuwerts AM, de Weerd V, Look MP, Puertas S, García N, Perkins AS, Bonifaci N, Skowron M, Gómez-Baldó L, Hernández V, Martínez-Aranda A, Martínez-Iniesta M, Serrat X, Cerón J, Brunet J, Barretina MP, Gil M, Falo C, Fernández A, Morilla I, Pernas S, Plà MJ, Andreu X, Seguí MA, Ballester R, Castellà E, Nellist M, Morales S, Valls J, Velasco A, Matias-Guiu X, Figueras A, Sánchez-Mut JV, Sánchez-Céspedes M, Cordero A, Gómez-Miragaya J, Palomero L, Gómez A, Gajewski TF, Cohen EE, Jesiotr M, Bodnar L, Quintela-Fandino M, López-Bigas N, Valdés-Mas R, Puente XS, Viñals F, Casanovas O, Graupera M, Hernández-Losa J, Ramón Y Cajal S, García-Alonso L, Saez-Rodriguez J, Esteller M, Sierra A, Martín-Martín N, Matheu A, Carracedo A, González-Suárez E, Nanjundan M, Cortés J, Lázaro C, Odero MD, Martens JW, Moreno-Bueno G, Barcellos-Hoff MH, Villanueva A, Gomis RR, Pujana MA. Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition. Oncogene. 2017. May 11;36(19):2737-2749
  • Vialas V, Colomé-Calls N, Abian J, Aloria K, Alvarez-Llamas G, Antúnez O, Arizmendi JM, Azkargorta M, Barceló-Batllori S, Barderas MG, Blanco F, Casal JI, Casas V, de la Torre C, Chicano-Gálvez E, Elortza F, Espadas G, Estanyol JM, Fernandez-Irigoyen J, Fernandez-Puente P, Fidalgo MJ, Fuentes M, Gay M, Gil C, Hainard A, Hernaez ML, Ibarrola N, Kopylov AT, Lario A, Lopez JA, López-Lucendo M, Marcilla M, Marina-Ramírez A, Marko-Varga G, Martín L, Mora MI, Morato-López E, Muñoz J, Odena MA, de Oliveira E, Orera I, Ortea I, Pasquarello C, Ray KB, Rezeli M, Ruppen I, Sabidó E, Del Pino MM, Sancho J, Santamaría E, Vazquez J, Vilaseca M, Vivanco F, Walters JJ, Zgoda VG, Corrales FJ, Canals F, Paradela A. A multicentric study to evaluate the use of relative retention times in targeted proteomics. J Proteomics. 2017 Jan 30;152:138-149.
  • Llombart V, Trejo SA, Bronsoms S, Morancho A, Feifei M, Faura J, García-Berrocoso T, Simats A, Rosell A, Canals F, Hernández-Guillamón M, Montaner J. Profiling and identification of new proteins involved in brain ischemia using MALDI-imaging-mass-spectrometry. J Proteomics.2017Jan 30;152:243-253.
  • Llombart V, García-Berrocoso T, Bech-Serra JJ, Simats A, Bustamante A, Giralt D, Reverter-Branchat G, Canals F, Hernández-Guillamon M, Montaner J. Characterization of secretomes from a human blood brain barrier endothelial cells in-vitro model after ischemia by stable isotope labeling with aminoacids in cell culture (SILAC). J Proteomics. 2016 Feb 5; 133:100-12.
  • Canals F, Elortza F, Paradela A, Corthals G, Camenzuli M, Muñoz A, Schiltz O, Gonzalez de Peredo A, Sickman A, Borchers C, Corrales FJ. The EuPA Standardization Initiative. EuPA Open Proteomics.2016: 31-32.
  • Scholz E, Mestre-Ferrer A, Daura X, García-Medel N, Carrascal M, James EA, Kwok WW, Canals F, Alvarez I. A comparative analysis of the peptide repertoires of HLA-DR molecules differentially associated to rheumatoid arthritis. Arthritis Rheumatol. 2016 Oct; 68(10): 2412-21.
  • Aguilera Ó, González-Sancho JM, Zazo S, Rincón R, Fernández AF, Tapia O, Canals F, Morte B, Calvanese V, Orgaz JL, Niell N, Aguilar S, Freije JM, Graña O, Pisano DG, Borrero A, Martínez-Useros J, Jiménez B, Fraga MF, García-Foncillas J, López-Otín C, Lafarga M, Rojo F, Muñoz A. Nuclear DICKKOPF-1 as a biomarker of chemoresistance and poor clinical outcome in colorectal cancer.Oncotarget 2015 Mar; 6(8): 5903-17
  • Alvarez I, Collado JA, Colobran R, Carrascal M, Ciudad MT, Canals F, James EA, Kwok WW, Gärtner M, Kyewski B, Pujol-Borrell R, Jaraquemada D. Central T cell tolerance: Identification of tissue-restricted autoantigens in the thymus HLA-DR peptidome. J. Autoimmun. 2015 Jun; 60: 12-9
  • Tababat-Khani P, de la Torre C, Canals F, Bennet H, Simó R, Hernández C, Fex M, Agardh CD, Hansson O, Agardh E. Photocoagulation of human retinal pigment epithelium in vitro: unravelling the effects on ARPE-19 by transcriptomics and proteomics. Acta Ophthalmol 2015 Jun; 93(4): 348-54
  • Rosa M, Bech-Serra JJ, Canals F, Zajac JM, Talmont F, Arsequell G, Valencia G. Optimized Proteomic Mass Spectrometry Characterization of Recombinant Human μ-Opioid Receptor Functionally Expressed in Pichia pastoris Cell Lines. J. Proteome Res. 2015 Aug; 14(8): 3162-73
  • Vilà-Rico M, Colomé-Calls N, Martín-Castel L, Gay M, Azorín S, Vilaseca M, Planas A, Canals F. Quantitative analysis of post-translational modifications in human serum transthyretin associated with familial amyloidotic polyneuropathy by targeted LC-MS and intact protein MS. J Proteomics 2015 Sep; 127: 234-46
  • Ferrer-Mayorga G, Alvarez-Díaz S, Valle N, De Las Rivas J, Mendes M, Barderas R, Canals F, Tapia O, Casal JI, Lafarga M, Muñoz A. Cystatin D locates in the nucleus at sites of active transcription and modulates gene and protein expression. J. Biol. Chem. 2015 Oct; 290(44): 26533-48
  • Pedersen K, Canals F, Prat A, Tabernero J, Arribas J. PELO negatively regulates HER receptor signalling and metastasis. Oncogene 2014 Feb; 33(9): 1190-7
  • Martino-Echarri E, Fernández-Rodríguez R, Bech-Serra JJ, Plaza-Calonge Mdel C, Vidal N, Casal C, Colomé N, Seoane J, Canals F, Rodríguez-Manzaneque JC. Relevance of IGFBP2 proteolysis in glioma and contribution of the extracellular protease ADAMTS1. Oncotarget 2014 Jun; 5(12): 4295-304
  • Segura V, Medina-Aunon JA, Mora MI, Martínez-Bartolomé S, Abian J, Aloria K, Antúnez O, Arizmendi JM, Azkargorta M, Barceló-Batllori S, Beaskoetxea J, Bech-Serra JJ, Blanco F, Monteiro MB, Cáceres D, Canals F, Carrascal M, Casal JI, Clemente F, Colomé N, Dasilva N, Díaz P, Elortza F, Fernández-Puente P, Fuentes M, Gallardo O, Gharbi SI, Gil C, González-Tejedo C, Hernáez ML, Lombardía M, Lopez-Lucendo M, Marcilla M, Mato JM, Mendes M, Oliveira E, Orera I, Pascual-Montano A, Prieto G, Ruiz-Romero C, Sánchez del Pino MM, Tabas-Madrid D, Valero ML, Vialas V, Villanueva J, Albar JP, Corrales FJ. Surfing transcriptomic landscapes. A step beyond the annotation of chromosome 16 proteome. J. Proteome Res. 2014 Jan; 13(1): 158-72
  • Juliachs M, Pujals M, Bellio C, Meo-Evoli N, Duran JM, Zamora E, Parés M, Suñol A, Méndez O, Sánchez-Pla A, Canals F, Saura C, Villanueva J. Circulating SOD2 Is a Candidate Response Biomarker for Neoadjuvant Therapy in Breast Cancer. Cancers (Basel). 2022 Aug 10;14(16):3858.
  • Bellio C, Emperador M, Castellano P, Gris-Oliver A, Canals F, Sánchez-Pla A, Zamora E, Arribas J, Saura C, Serra V, Tabernero J, Littlefield BA, Villanueva J. GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells. Cancers (Basel). 2022 May 23;14(10):2562.
  • Pujals M, Resar L, Villanueva J. HMGA1, Moonlighting Protein Function, and Cellular Real Estate: Location, Location, Location! Biomolecules. 2021 Sep 9;11(9):1334.
  • Méndez O, Pérez J, Soberino J, Racca F, Cortés J, Villanueva J. Clinical Implications of Extracellular HMGA1 in Breast Cancer. Int J Mol Sci. 2019. 20(23), 5950.
  • Méndez O, Peg V, Salvans C, Pujals M, Fernández Y, Abasolo I, Pérez J, Matres A, Valeri M, Gregori J, Villarreal L, Schwartz S Jr, Ramon Y Cajal S, Tabernero J, Cortés J, Arribas J, Villanueva J. Extracellular HMGA1 Promotes Tumor Invasion and Metastasis in Triple-Negative Breast Cancer. Clin Cancer Res. 2018 Dec 15;24(24):6367-6382
  • Méndez O, Villanueva J. Challenges and opportunities for cell line secretomes in cancer proteomics.Proteomics Clin Appl. 2015;9(3-4):348-357.
  • Katsila T, Juliachs M, Gregori J, Macarulla T, Villarreal L, Bardelli A, Torrance C, Elez E, Tabernero J, Villanueva J. Circulating pEGFR is a candidate response biomarker of cetuximab therapy in colorectal cancer. Clin. Cancer Res. 2014 Dec; 20(24): 6346-56
  • Villarreal L, Méndez O, Salvans C, Gregori J, Baselga J, Villanueva J*. Unconventionalsecretion is a major contributor of cancer cell line secretomes. Mol Cell Proteomics. 2013, 12(5):1046-60.
  • Gregori J, Méndez O, Katsila T, Pujals M, Salvans C, Villarreal L, Arribas J, Tabernero J, Sánchez A, Villanueva J. Enhancing the Biological Relevance of Secretome-Based Proteomics by Linking Tumor Cell Proliferation and Protein Secretion. J. Proteome Res. 2014 Jul;
  • Gregori J, Villarreal L, Sánchez A, Baselga J, Villanueva J. An effect size filter improves the reproducibility in spectral counting-based comparative proteomics. J Proteomics 2013 Dec; 95: 55-65
  • Gregori J, Villarreal L, Méndez O, Sánchez A, Baselga J, Villanueva J. Batch effects correction improves the sensitivity of significance tests in spectral counting-based comparative discovery proteomics. J Proteomics 2012 Jul; 75(13): 3938-51
  • Lawlor K, Nazarian A, Lacomis L, Tempst P, Villanueva J*. Pathway-based biomarker search by high-throughput proteomics profiling of secretomes. J Proteome Research. 2009. 8(3):1489-503.

 

Totes les publicacions

  • Puig N, Rives J, Estruch M, Aguilera-Simon A, Rotllan N, Camacho M, Colomé N, Canals F, Sánchez-Quesada JL, Benitez S. Presence of Ceramidase Activity in Electronegative LDL. Int J Mol Sci. 2022 Dec 22;24(1):165. doi: 10.3390/ijms24010165. PMID: 36613609; PMCID: PMC9820682.
  • McGrail K, Granado-Martínez P, Esteve-Puig R, García-Ortega S, Ding Y, Sánchez-Redondo S, Ferrer B, Hernandez-Losa J, Canals F, Manzano A, Navarro-Sabaté A, Bartrons R, Yanes O, Pérez-Alea M, Muñoz-Couselo E, Garcia-Patos V, Recio JA. BRAF activation by metabolic stress promotes glycolysis sensitizing NRASQ61-mutated melanomas to targeted therapy. Nat Commun. 2022 Nov 19;13(1):7113.
  • Juliachs M, Pujals M, Bellio C, Meo-Evoli N, Duran JM, Zamora E, Parés M, Suñol A, Méndez O, Sánchez-Pla A, Canals F, Saura C, Villanueva J. Circulating SOD2 Is a Candidate Response Biomarker for Neoadjuvant Therapy in Breast Cancer. Cancers (Basel). 2022 Aug 10;14(16):3858. doi: 10.3390/cancers14163858. PMID: 36010852; PMCID: PMC9405919.
  • Barbero F, Michelini S, Moriones OH, Patarroyo J, Rosell J, F Gusta M, Vitali M, Martín L, Canals F, Duschl A, Horejs-Hoeck J, Mondragón L, Bastús NG, Puntes V. Role of Common Cell Culture Media Supplements on Citrate-Stabilized Gold Nanoparticle Protein Corona Formation, Aggregation State, and the Consequent Impact on Cellular Uptake. Bioconjug Chem. 2022 Aug 17;33(8):1505-1514. doi: 10.1021/acs.bioconjchem.2c00232. Epub 2022 Jul 19. PMID: 35852911.
  • Bellio C, Emperador M, Castellano P, Gris-Oliver A, Canals F, Sánchez-Pla A, Zamora E, Arribas J, Saura C, Serra V, Tabernero J, Littlefield BA, Villanueva J. GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells. Cancers (Basel). 2022 May 23;14(10):2562. doi: 10.3390/cancers14102562. PMID: 35626166; PMCID: PMC9139899.
  • Colomé N, Abian J, Aloria K, Arizmendi JM, Barceló-Batllori S, Braga-Lagache S, Burlet-Schiltz O, Carrascal M, Casal JI, Chicano-Gálvez E, Chiva C, Clemente LF, Elortza F, Estanyol JM, Fernandez-Irigoyen J, Fernández-Puente P, Fidalgo MJ, Froment C, Fuentes M, Fuentes-Almagro C, Gay M, Hainard A, Heller M, Hernández ML, Ibarrola N, Iloro I, Kieselbach T, Lario A, Locard-Paulet M, Marina-Ramírez A, Martín L, Morato-López E, Muñoz J, Navajas R, Odena MA, Odriozola L, de Oliveira E, Paradela A, Pasquarello C, de Los Rios V, Ruiz-Romero C, Sabidó E, Sánchez Del Pino M, Sancho J, Santamaría E, Schaeffer-Reiss C, Schneider J, de la Torre C, Valero ML, Vilaseca M, Wu S, Wu L, Ximénez de Embún P, Canals F, Corrales FJ; ProteoRed-ISCIII; EuPA. Multi-laboratory experiment PME11 for the standardization of phosphoproteome analysis. J Proteomics. 2022 Jan 16;251:104409. doi: 10.1016/j.jprot.2021.104409. Epub 2021 Nov 7. PMID: 34758407.
  • Ramiro L, García-Berrocoso T, Briansó F, Goicoechea L, Simats A, Llombart V, Gonzalo R, Hainard A, Martínez-Saez E, Canals F, Sanchez JC, Sánchez-Pla A, Montaner J. Integrative Multi-omics Analysis to Characterize Human Brain Ischemia. Mol Neurobiol. 2021 Aug;58(8):4107-4121.
  • Colomé N, Abian J, Aloria K, Arizmendi JM, Barceló-Batllori S, Braga-Lagache S, Burlet-Schiltz O, Carrascal M, Casal JI, Chicano-Gálvez E, Chiva C, Clemente LF, Elortza F, Estanyol JM, Fernandez-Irigoyen J, Fernández-Puente P, Fidalgo MJ, Froment C, Fuentes M, Fuentes-Almagro C, Gay M, Hainard A, Heller M, Hernández ML, Ibarrola N, Iloro I, Kieselbach T, Lario A, Locard-Paulet M, Marina-Ramírez A, Martín L, Morato-López E, Muñoz J, Navajas R, Odena MA, Odriozola L, de Oliveira E, Paradela A, Pasquarello C, de Los Rios V, Ruiz-Romero C, Sabidó E, Sánchez Del Pino M, Sancho J, Santamaría E, Schaeffer-Reiss C, Schneider J, de la Torre C, Valero ML, Vilaseca M, Wu S, Wu L, Ximénez de Embún P, Canals F, Corrales FJ; ProteoRed-ISCIII; EuPA. Multi-laboratory experiment PME11 for the standardization of phosphoproteome analysis. J Proteomics. 2022 Jan 16;251:104409. Epub 2021 Nov 7.
  • Arreal L, Piva M, Fernández S, Revandkar A, Schaub- Clerigué A, Villanueva J, Zabala-Letona A, Pujana M, Astobiza I, Cortazar AR, Hermanova I, Bozal-Basterra L, Arruabarrena-Aristorena A, Crespo JR, Valcarcel-Jimenez L, Zúñiga-García P, Canals F, Torrano V, Barrio R, Sutherland JD, Alimonti A, Martin-Martin N, Carracedo A. Targeting PML in triple negative breast cancer elicits growth suppression and senescence. Cell Death Differ. 2019 Oct 1.
  • Garcia-Puig A, Mosquera JL, Jiménez-Delgado S, García-Pastor C, Jorba I, Navajas D, Canals F, Raya A. Proteomics analysis of extracellular matrix remodeling during zebrafish heart regeneration. Mol Cell Proteomics. 2019 Sep;18(9):1745-1755.
  • Marcelino I, Colomé-Calls N, Holzmuller P, Lisacek F, Reynaud Y, Canals F, Vachiéry N. Sweet and Sour Ehrlichia: Glycoproteomics and Phosphoproteomics Reveal New Players in Ehrlichia ruminantium Physiology and Pathogenesis. Front Microbiol. 2019 Mar 15;10:450.
  • Marinelli P, Navarro S, Baño-Polo M, Morel B, Graña-Montes R, Sabe A, Canals F, Fernandez MR, Conejero-Lara F, Ventura S. Global Protein Stabilization Does Not Suffice to Prevent Amyloid Fibril Formation. ACS Chem Biol. 2018 Aug 17, 13(8):2094-2105.
  • Simats A, García-Berrocoso T, Penalba A, Giralt D, Llovera G, Jiang Y, Ramiro L, Bustamante A, Martinez-Saez E, Canals F, Wang X, Liesz A, Rosell A, Montaner J. CCL23: A new CC chemokine involved in human brain damage. J Intern Med. 2018 May; 283(5):461-475.
  • García-Berrocoso T, Llombart V, Colàs-Campàs L, Hainard A, Licker V, Penalba A, Ramiro L, Simats A, Bustamante A, Martínez-Saez E, Canals F, Sanchez JC, Montaner J. Single Cell Immuno-laser Microdissection Coupled to Label-free Proteomics to Reveal the Proteotypes of Human Brain Cells After Ischemia. Mol Cell Proteomics. 2018 Jan;17(1):175-189.
  • García-Berrocoso T, Llombart V, Colàs-Campàs L, Hainard A, Licker V, Penalba A, Ramiro L, Simats A, Bustamante A, Martínez-Saez E, Canals F, Sanchez JC, Montaner J. Single Cell Immuno-laser Microdissection Coupled to Label-free Proteomics to Reveal the Proteotypes of Human Brain Cells After Ischemia. Mol Cell Proteomics. 2017 Nov 13. [Epub ahead of print]
  • Fraga H, Pujols J, Gil-Garcia M, Roque A, Bernardo-Seisdedos G, Santambrogio C, Bech-Serra JJ, Canals F, Bernadó P, Grandori R, Millet O, Ventura S. Disulfide driven folding for a conditionally disordered protein. Sci Rep. 2017 Dec 5;7(1):16994
  • Mateo F, Arenas EJ, Aguilar H, Serra-Musach J, de Garibay GR, Boni J, Maicas M, Du S, Iorio F, Herranz-Ors C, Islam A, Prado X, Llorente A, Petit A, Vidal A, Català I, Soler T, Venturas G, Rojo-Sebastian A, Serra H, Cuadras D, Blanco I, Lozano J, Canals F, Sieuwerts AM, de Weerd V, Look MP, Puertas S, García N, Perkins AS, Bonifaci N, Skowron M, Gómez-Baldó L, Hernández V, Martínez-Aranda A, Martínez-Iniesta M, Serrat X, Cerón J, Brunet J, Barretina MP, Gil M, Falo C, Fernández A, Morilla I, Pernas S, Plà MJ, Andreu X, Seguí MA, Ballester R, Castellà E, Nellist M, Morales S, Valls J, Velasco A, Matias-Guiu X, Figueras A, Sánchez-Mut JV, Sánchez-Céspedes M, Cordero A, Gómez-Miragaya J, Palomero L, Gómez A, Gajewski TF, Cohen EE, Jesiotr M, Bodnar L, Quintela-Fandino M, López-Bigas N, Valdés-Mas R, Puente XS, Viñals F, Casanovas O, Graupera M, Hernández-Losa J, Ramón Y Cajal S, García-Alonso L, Saez-Rodriguez J, Esteller M, Sierra A, Martín-Martín N, Matheu A, Carracedo A, González-Suárez E, Nanjundan M, Cortés J, Lázaro C, Odero MD, Martens JW, Moreno-Bueno G, Barcellos-Hoff MH, Villanueva A, Gomis RR, Pujana MA. Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition. Oncogene 2017. May 11;36(19):2737-2749
  • Vialas V, Colomé-Calls N, Abian J, Aloria K, Alvarez-Llamas G, Antúnez O, Arizmendi JM, Azkargorta M, Barceló-Batllori S, Barderas MG, Blanco F, Casal JI, Casas V, de la Torre C, Chicano-Gálvez E, Elortza F, Espadas G, Estanyol JM, Fernandez-Irigoyen J, Fernandez-Puente P, Fidalgo MJ, Fuentes M, Gay M, Gil C, Hainard A, Hernaez ML, Ibarrola N, Kopylov AT, Lario A, Lopez JA, López-Lucendo M, Marcilla M, Marina-Ramírez A, Marko-Varga G, Martín L, Mora MI, Morato-López E, Muñoz J, Odena MA, de Oliveira E, Orera I, Ortea I, Pasquarello C, Ray KB, Rezeli M, Ruppen I, Sabidó E, Del Pino MM, Sancho J, Santamaría E, Vazquez J, Vilaseca M, Vivanco F, Walters JJ, Zgoda VG, Corrales FJ, Canals F, Paradela A. A multicentric study to evaluate the use of relative retention times in targeted proteomics. J Proteomics. 2017 Jan 30;152:138-149.
  • Llombart V, Trejo SA, Bronsoms S, Morancho A, Feifei M, Faura J, García-Berrocoso T, Simats A, Rosell A, Canals F, Hernández-Guillamón M, Montaner J. Profiling and identification of new proteins involved in brain ischemia using MALDI-imaging-mass-spectrometry. J Proteomics. 2017Jan 30;152:243-253.
  • Hidalgo-Galiana A, Monge M, Biron DG, Canals F, Ribera I, Cieslak A. Protein expression parallels thermal tolerance and ecologic changes in the diversification of a diving beetle species complex. Heredity (Edinb). 2016; 116(1):114-23.
  • Llombart V, García-Berrocoso T, Bech-Serra JJ, Simats A, Bustamante A, Giralt D, Reverter-Branchat G, Canals F, Hernández-Guillamon M, Montaner J. Characterization of secretomes from a human blood brain barrier endothelial cells in-vitro model after ischemia by stable isotope labeling with aminoacids in cell culture (SILAC). J Proteomics. 2016; 133:100-12.
  • Canals F, Elortza F, Paradela A, Corthals G, Camenzuli M, Muñoz A, Schiltz O, Gonzalez de Peredo A, Sickman A, Borchers C, Corrales FJ The EuPA Standardization Initiative. EuPA Open Proteomics. 2016: 31-32.
  • Scholz E, Mestre-Ferrer A, Daura X, García-Medel N, Carrascal M, James EA, Kwok WW, Canals F, Alvarez I. A comparative analysis of the peptide repertoires of HLA-DR molecules differentially associated to rheumatoid arthritis. Arthritis Rheumatol. 2016; 68(10): 2412-21.
  • Novoa-Herran S, Umana-Perez A, Canals F, Sanchez-Gomez M.Serum depletion induces changes in protein expression in the trophoblast-derived cell line HTR-8/SVneo. Cellular & Molecular Biology Letters. 2016; 21:22
  • Aguilera Ó, González-Sancho JM, Zazo S, Rincón R, Fernández AF, Tapia O, Canals F, Morte B, Calvanese V, Orgaz JL, Niell N, Aguilar S, Freije JM, Graña O, Pisano DG, Borrero A, Martínez-Useros J, Jiménez B, Fraga MF, García-Foncillas J, López-Otín C, Lafarga M, Rojo F, Muñoz A. Nuclear DICKKOPF-1 as a biomarker of chemoresistance and poor clinical outcome in colorectal cancer.Oncotarget 2015 Mar; 6(8): 5903-17
  • Alvarez I, Collado JA, Colobran R, Carrascal M, Ciudad MT, Canals F, James EA, Kwok WW, Gärtner M, Kyewski B, Pujol-Borrell R, Jaraquemada D. Central T cell tolerance: Identification of tissue-restricted autoantigens in the thymus HLA-DR peptidome. J. Autoimmun. 2015 Jun; 60: 12-9
  • Tababat-Khani P, de la Torre C, Canals F, Bennet H, Simó R, Hernández C, Fex M, Agardh CD, Hansson O, Agardh E. Photocoagulation of human retinal pigment epithelium in vitro: unravelling the effects on ARPE-19 by transcriptomics and proteomics. Acta Ophthalmol 2015 Jun; 93(4): 348-54
  • Rosa M, Bech-Serra JJ, Canals F, Zajac JM, Talmont F, Arsequell G, Valencia G. Optimized Proteomic Mass Spectrometry Characterization of Recombinant Human μ-Opioid Receptor Functionally Expressed in Pichia pastoris Cell Lines. J. Proteome Res. 2015 Aug; 14(8): 3162-73
  • Vilà-Rico M, Colomé-Calls N, Martín-Castel L, Gay M, Azorín S, Vilaseca M, Planas A, Canals F. Quantitative analysis of post-translational modifications in human serum transthyretin associated with familial amyloidotic polyneuropathy by targeted LC-MS and intact protein MS. J Proteomics 2015 Sep; 127: 234-46
  • Ferrer-Mayorga G, Alvarez-Díaz S, Valle N, De Las Rivas J, Mendes M, Barderas R, Canals F, Tapia O, Casal JI, Lafarga M, Muñoz A. Cystatin D locates in the nucleus at sites of active transcription and modulates gene and protein expression. J. Biol. Chem. 2015 Oct; 290(44): 26533-48
  • Pedersen K, Canals F, Prat A, Tabernero J, Arribas J. PELO negatively regulates HER receptor signalling and metastasis. Oncogene 2014 Feb; 33(9): 1190-7
  • Martino-Echarri E, Fernández-Rodríguez R, Bech-Serra JJ, Plaza-Calonge Mdel C, Vidal N, Casal C, Colomé N, Seoane J, Canals F, Rodríguez-Manzaneque JC. Relevance of IGFBP2 proteolysis in glioma and contribution of the extracellular protease ADAMTS1. Oncotarget 2014 Jun; 5(12): 4295-304
  • Segura V, Medina-Aunon JA, Mora MI, Martínez-Bartolomé S, Abian J, Aloria K, Antúnez O, Arizmendi JM, Azkargorta M, Barceló-Batllori S, Beaskoetxea J, Bech-Serra JJ, Blanco F, Monteiro MB, Cáceres D, Canals F, Carrascal M, Casal JI, Clemente F, Colomé N, Dasilva N, Díaz P, Elortza F, Fernández-Puente P, Fuentes M, Gallardo O, Gharbi SI, Gil C, González-Tejedo C, Hernáez ML, Lombardía M, Lopez-Lucendo M, Marcilla M, Mato JM, Mendes M, Oliveira E, Orera I, Pascual-Montano A, Prieto G, Ruiz-Romero C, Sánchez del Pino MM, Tabas-Madrid D, Valero ML, Vialas V, Villanueva J, Albar JP, Corrales FJ. Surfing transcriptomic landscapes. A step beyond the annotation of chromosome 16 proteome. J. Proteome Res. 2014 Jan; 13(1): 158-72
  • Fraga H, Bech-Serra JJ, Canals F, Ortega G, Millet O, Ventura S. The mitochondrial intermembrane space oxireductase Mia40 funnels the oxidative folding pathway of the cytochrome c oxidase assembly protein Cox19. J. Biol. Chem. 2014 Apr; 289(14): 9852-64
  • Hidalgo-Galiana A, Monge M, Biron DG, Canals F, Ribera I, Cieslak A. Reproducibility and consistency of proteomic experiments on natural populations of a non-model aquatic insect. PLoS ONE 2014; 9(8): e104734
  • Esteve-Puig R, Gil R, González-Sánchez E, Bech-Serra JJ, Grueso J, Hernandez-Losa J, Moliné T, Canals F, Ferrer B, Cortes J, Bastian B, Ramón y Cajal S, Martín-Caballero J, Flores JM, Vivancos A, Garcia-Patos V, Recio JA. A mouse model uncovers LKB1 as an UVB-induced DNA damage sensor mediating CDKN1A (p21WAF1/CIP1) degradation. PLoS Genet. 2014 Oct; 10(10): e1004721
  • Segura V, Medina-Aunon JA, Guruceaga E, Gharbi SI, González-Tejedo C, Sánchez del Pino MM, Canals F, Fuentes M, Casal JI, Martínez-Bartolomé S, Elortza F, Mato JM, Arizmendi JM, Abian J, Oliveira E, Gil C, Vivanco F, Blanco F, Albar JP, Corrales FJ. Spanish human proteome project: dissection of chromosome 16. J. Proteome Res. 2013 Jan; 12(1): 112-22
  • Morancho B, Parra-Palau JL, Ibrahim YH, Bernadó Morales C, Peg V, Bech-Serra JJ, Pandiella A, Canals F, Baselga J, Rubio I, Arribas J. A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers. Oncogene 2013 Mar; 32(11): 1452-9
  • Angelini PD, Zacarias Fluck MF, Pedersen K, Parra-Palau JL, Guiu M, Bernadó Morales C, Vicario R, Luque-García A, Navalpotro NP, Giralt J, Canals F, Gomis RR, Tabernero J, Baselga J, Villanueva J, Arribas J. Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence.Cancer Res. 2013 Jan; 73(1): 450-8
  • Martínez-Bartolomé S, Deutsch EW, Binz PA, Jones AR, Eisenacher M, Mayer G, Campos A, Canals F, Bech-Serra JJ, Carrascal M, Gay M, Paradela A, Navajas R, Marcilla M, Hernáez ML, Gutiérrez-Blázquez MD, Velarde LF, Aloria K, Beaskoetxea J, Medina-Aunon JA, Albar JP. Guidelines for reporting quantitative mass spectrometry based experiments in proteomics. J Proteomics 2013 Dec; 95: 84-8
  • Hernández C, García-Ramírez M, Colomé N, Corraliza L, García-Pascual L, Casado J, Canals F, Simó R. Identification of new pathogenic candidates for diabetic macular edema using fluorescence-based difference gel electrophoresis analysis. Diabetes Metab. Res. Rev. 2013 Sep; 29(6): 499-506
  • Collado JA, Alvarez I, Ciudad MT, Espinosa G, Canals F, Pujol-Borrell R, Carrascal M, Abian J, Jaraquemada D. Composition of the HLA-DR-associated human thymus peptidome. Eur. J. Immunol. 2013 Sep; 43(9): 2273-82
  • García-Berrocoso T, Penalba A, Boada C, Giralt D, Cuadrado E, Colomé N, Dayon L, Canals F, Sánchez JC, Rosell A, Montaner J. From brain to blood: New biomarkers for ischemic stroke prognosis. J Proteomics 2013 Dec; 94: 138-48
  • Lecube A, Poca MA, Colomé N, Bech-Serra JJ, Hernández C, García-Ramírez M, Gandara D, Canals F, Simó R. Proteomic analysis of cerebrospinal fluid from obese women with idiopathic intracranial hypertension: a new approach for identifying new candidates in the pathogenesis of obesity. J. Neuroendocrinol. 2012 Jun; 24(6): 944-52
  • Alonso-del-Rivero M, Trejo SA, Reytor ML, Rodriguez-de-la-Vega M, Delfín J, Díaz J, González-González Y, Canals F, Chávez MA, Aviles FX. Tri-domain bifunctional inhibitor of metallocarboxypeptidases A and serine proteases isolated from marine annelid Sabellastarte magnifica. J. Biol. Chem. 2012 May; 287(19): 15427-38
  • Koziol A, Gonzalo P, Mota A, Pollán Á, Lorenzo C, Colomé N, Montaner D, Dopazo J, Arribas J, Canals F, Arroyo AG. The protease MT1-MMP drives a combinatorial proteolytic program in activated endothelial cells. FASEB J. 2012 Nov; 26(11): 4481-94
  • Párraga-Niño N, Colomé-Calls N, Canals F, Querol E, Ferrer-Navarro M. A comprehensive proteome of Mycoplasma genitalium. J. Proteome Res. 2012 Jun; 11(6): 3305-16
  • Andreu-Pérez P, Esteve-Puig R, de Torre-Minguela C, López-Fauqued M, Bech-Serra JJ, Tenbaum S, García-Trevijano ER, Canals F, Merlino G, Avila MA, Recio JA. Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction amplitude and cell fate through CRAF. Sci Signal 2011 Sep; 4(190): ra58
  • Malapeira J, Esselens C, Bech-Serra JJ, Canals F, Arribas J. ADAM17 (TACE) regulates TGFβ signaling through the cleavage of vasorin. Oncogene 2011 Apr; 30(16): 1912-22
  • Colomé N, Collado J, Bech-Serra JJ, Liiv I, Antón LC, Peterson P, Canals F, Jaraquemada D, Alvarez I. Increased apoptosis after autoimmune regulator expression in epithelial cells revealed by a combined quantitative proteomics approach. J. Proteome Res. 2010 May; 9(5): 2600-9
  • Hernández C, García-Ramírez M, Colomé N, Villarroel M, Corraliza L, García-Pacual L, Casado J, Canals F, Simó R. New pathogenic candidates for diabetic macular edema detected by proteomic analysis. Diabetes Care 2010 Jul; 33(7): e92
  • Bancells C, Canals F, Benitez S, Colomé N, Julve J, Ordóñez-Llanos J, Sanchez-Quesada JL. Proteomic analysis of electronegative low-density lipoprotein. J. Lipid Res. 2010 Dec; 51(12): 3508-15
  • Cuadrado E, Rosell A, Colomé N, Hernández-Guillamon M, García-Berrocoso T, Ribo M, Alcazar A, Ortega-Aznar A, Salinas M, Canals F, Montaner J. The proteome of human brain after ischemic stroke.J. Neuropathol. Exp. Neurol. 2010 Nov; 69(11): 1105-15
  • Esselens C, Malapeira J, Colomé N, Casal C, Rodríguez-Manzaneque JC, Canals F, Arribas J. The cleavage of semaphorin 3C induced by ADAMTS1 promotes cell migration. J. Biol. Chem. 2010 Jan; 285(4): 2463-73
  • García-Castillo J, Pedersen K, Angelini PD, Bech-Serra JJ, Colomé N, Cunningham MP, Parra-Palau JL, Canals F, Baselga J, Arribas J. HER2 carboxyl-terminal fragments regulate cell migration and cortactin phosphorylation. J. Biol. Chem. 2009 Sep; 284(37): 25302-13
  • Bech-Serra JJ, Borthwick A, Colomé N, Albar JP, Wells M, Sánchez del Pino M, Canals F. A multi-laboratory study assessing reproducibility of a 2D-DIGE differential proteomic experiment. J Biomol Tech 2009 Dec; 20(5): 293-6
  • García-Ramírez M, Hernández C, Villarroel M, Canals F, Alonso MA, Fortuny R, Masmiquel L, Navarro A, García-Arumí J, Simó R. Interphotoreceptor retinoid-binding protein (IRBP) is downregulated at early stages of diabetic retinopathy. Diabetologia 2009 Dec; 52(12): 2633-41
  • Hellin JL, Bech-Serra JJ, Moctezuma EL, Chocron S, Santin S, Madrid A, Vilalta R, Canals F, Torra R, Meseguer A, Nieto JL. Very low-molecular-mass fragments of albumin in the plasma of patients with focal segmental glomerulosclerosis. Am. J. Kidney Dis. 2009 Nov; 54(5): 871-80
  • Alonso-del-Rivero M, Trejo SA, Rodríguez de la Vega M, González Y, Bronsoms S, Canals F, Delfín J, Díaz J, Aviles FX, Chávez MA. A novel metallocarboxypeptidase-like enzyme from the marine annelid Sabellastarte magnifica–a step into the invertebrate world of proteases. FEBS J. 2009 Sep; 276(17): 4875-90
  • Monge M, Doll A, Colas E, Gil-Moreno A, Castellví J, Garcia A, Colomé N, Perez-Benavente A, Pedrola N, Lopez-Lopez R, Dolcet X, Ramón y Cajal S, Xercavins J, Matias-Guiu X, Canals F, Reventos J, Abal M. Subtractive proteomic approach to the endometrial carcinoma invasion front. J. Proteome Res. 2009 Oct; 8(10): 4676-84
  • Trejo SA, López LM, Caffini NO, Natalucci CL, Canals F, Aviles FX. Sequencing and characterization of asclepain f: the first cysteine peptidase cDNA cloned and expressed from Asclepias fruticosa latex. Planta 2009 Jul; 230(2): 319-28
  • Monge M, Colas E, Doll A, Gil-Moreno A, Castellví J, Diaz B, Gonzalez M, Lopez-Lopez R, Xercavins J, Carreras R, Alameda F, Canals F, Gabrielli F, Reventos J, Abal M. Proteomic approach to ETV5 during endometrial carcinoma invasion reveals a link to oxidative stress. Carcinogenesis 2009 Aug; 30(8): 1288-97
  • Esteve-Puig R, Canals F, Colomé N, Merlino G, Recio JA. Uncoupling of the LKB1-AMPKalpha energy sensor pathway by growth factors and oncogenic BRAF. PLoS ONE 2009; 4(3): e4771
  • Lyakhovich A, Bech-Serra JJ, Canals F, Surralles J. Quick two-dimensional differential in gel electrophoresis-based method to determine length and secondary structures of telomeric DNA. Anal. Biochem. 2009 Jan; 384(2): 356-8
  • Bech-Serra JJ, Santiago-Josefat B, Esselens C, Saftig P, Baselga J, Arribas J, Canals F. Proteomic identification of desmoglein 2 and activated leukocyte cell adhesion molecule as substrates of ADAM17 and ADAM10 by difference gel electrophoresis. Mol. Cell. Biol. 2006 Jul; 26(13): 5086-95
  • Canals F, Colomé N, Ferrer C, Plaza-Calonge Mdel C, Rodríguez-Manzaneque JC. Identification of substrates of the extracellular protease ADAMTS1 by DIGE proteomic analysis. Proteomics 2006 Apr; 6 Suppl 1: S28-35
  • Juliachs M, Pujals M, Bellio C, Meo-Evoli N, Duran JM, Zamora E, Parés M, Suñol A, Méndez O, Sánchez-Pla A, Canals F, Saura C, Villanueva J. Circulating SOD2 Is a Candidate Response Biomarker for Neoadjuvant Therapy in Breast Cancer. Cancers (Basel). 2022 Aug 10;14(16):3858.
  • Bellio C, Emperador M, Castellano P, Gris-Oliver A, Canals F, Sánchez-Pla A, Zamora E, Arribas J, Saura C, Serra V, Tabernero J, Littlefield BA, Villanueva J. GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells. Cancers (Basel). 2022 May 23;14(10):2562.
  • Pujals M, Resar L, Villanueva J. HMGA1, Moonlighting Protein Function, and Cellular Real Estate: Location, Location, Location! Biomolecules. 2021 Sep 9;11(9):1334.
  • Méndez O, Pérez J, Soberino J, Racca F, Cortés J, Villanueva J. Clinical Implications of Extracellular HMGA1 in Breast Cancer. Int J Mol Sci. 2019, 20(23), 5950.
  • Arreal L, Piva M, Fernández S, Revandkar A, Schaub-Clerigué A, Villanueva J, Zabala-Letona A, Pujana M, Astobiza I, Cortazar AR, Hermanova I, Bozal-Basterra L, Arruabarrena-Aristorena A, Crespo JR, Valcarcel-Jimenez L, Zúñiga-García P, Canals F, Torrano V, Barrio R, Sutherland JD, Alimonti A, Martin-Martin N, Carracedo A.Targeting PML in triple negative breast cancer elicits growth suppression and senescence. Cell Death Differ. 2019 Oct 1. doi: 10.1038/s41418-019-0407-5.
  • Méndez O, Peg V, Salvans C, Pujals M, Fernández Y, Abasolo I, Pérez J, Matres A, Valeri M, Gregori J, Villarreal L, Schwartz S Jr, Ramon Y Cajal S, Tabernero J, Cortés J, Arribas J, Villanueva J. Extracellular HMGA1 Promotes Tumor Invasion and Metastasis in Triple-Negative Breast Cancer. Clin Cancer Res. 2018 Dec 15;24(24):6367-6382
  • Zacarias-Fluck MF, Morancho B, Vicario R, Luque Garcia A, Escorihuela M, Villanueva J, Rubio IT, Arribas J. Effect of cellular senescence on the growth of HER2-positive breast cancers. J. Natl. Cancer Inst. 2015 May; 107(5)
  • Morancho B, Martínez-Barriocanal Á, Villanueva J, Arribas J. Role of ADAM17 in the non-cell autonomous effects of oncogene-induced senescence. Breast Cancer Res. 2015; 17: 106
  • Katsila T, Juliachs M, Gregori J, Macarulla T, Villarreal L, Bardelli A, Torrance C, Elez E, Tabernero J, Villanueva J. Circulating pEGFR is a candidate response biomarker of cetuximab therapy in colorectal cancer. Clin. Cancer Res. 2014 Dec; 20(24): 6346-56
  • Nazarian A, Lawlor K, Yi SS, Philip J, Ghosh M, Yaneva M, Villanueva J, Saghatelian A, Assel M, Vickers AJ, Eastham JA, Scher HI, Carver BS, Lilja H, Tempst P. Inhibition of circulating dipeptidyl peptidase 4 activity in patients with metastatic prostate cancer. Mol. Cell Proteomics 2014 Nov; 13(11): 3082-96
  • Gregori J, Méndez O, Katsila T, Pujals M, Salvans C, Villarreal L, Arribas J, Tabernero J, Sánchez A, Villanueva J. Enhancing the Biological Relevance of Secretome-Based Proteomics by Linking Tumor Cell Proliferation and Protein Secretion. J. Proteome Res. 2014 Jul;
  • Segura V, Medina-Aunon JA, Mora MI, Martínez-Bartolomé S, Abian J, Aloria K, Antúnez O, Arizmendi JM, Azkargorta M, Barceló-Batllori S, Beaskoetxea J, Bech-Serra JJ, Blanco F, Monteiro MB, Cáceres D, Canals F, Carrascal M, Casal JI, Clemente F, Colomé N, Dasilva N, Díaz P, Elortza F, Fernández-Puente P, Fuentes M, Gallardo O, Gharbi SI, Gil C, González-Tejedo C, Hernáez ML, Lombardía M, Lopez-Lucendo M, Marcilla M, Mato JM, Mendes M, Oliveira E, Orera I, Pascual-Montano A, Prieto G, Ruiz-Romero C, Sánchez del Pino MM, Tabas-Madrid D, Valero ML, Vialas V, Villanueva J, Albar JP, Corrales FJ. Surfing transcriptomic landscapes. A step beyond the annotation of chromosome 16 proteome. J. Proteome Res. 2014 Jan; 13(1): 158-72
  • Gregori J, Villarreal L, Sánchez A, Baselga J, Villanueva J. An effect size filter improves the reproducibility in spectral counting-based comparative proteomics. J Proteomics 2013 Dec; 95: 55-65
  • Angelini PD, Zacarias Fluck MF, Pedersen K, Parra-Palau JL, Guiu M, Bernadó Morales C, Vicario R, Luque-García A, Navalpotro NP, Giralt J, Canals F, Gomis RR, Tabernero J, Baselga J, Villanueva J, Arribas J. Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence.Cancer Res. 2013 Jan; 73(1): 450-8
  • Gregori J, Villarreal L, Méndez O, Sánchez A, Baselga J, Villanueva J. Batch effects correction improves the sensitivity of significance tests in spectral counting-based comparative discovery proteomics. J Proteomics 2012 Jul; 75(13): 3938-51
  • Sánchez A, Villanueva J. PI3K-based molecular signatures link high PI3K pathway activity with low ER levels in ER+ breast cancer. Expert Rev Proteomics 2010 Dec; 7(6): 819-21
  • Villanueva J, Nazarian A, Lawlor K, Tempst P. Monitoring peptidase activities in complex proteomes by MALDI-TOF mass spectrometry. Nat Protoc 2009; 4(8): 1167-83
  • Lawlor K, Nazarian A, Lacomis L, Tempst P, Villanueva J. Pathway-based biomarker search by high-throughput proteomics profiling of secretomes. J. Proteome Res. 2009 Mar; 8(3): 1489-503
  • Villanueva J, Nazarian A, Lawlor K, Yi SS, Robbins RJ, Tempst P. A sequence-specific exopeptidase activity test (SSEAT) for “functional” biomarker discovery. Mol. Cell Proteomics 2008 Mar; 7(3): 509-18
  • Villanueva J, Philip J, DeNoyer L, Tempst P. Data analysis of assorted serum peptidome profiles. Nat Protoc 2007; 2(3): 588-602
  • Villanueva J, Lawlor K, Toledo-Crow R, Tempst P. Automated serum peptide profiling. Nat Protoc 2006; 1(2): 880-91
  • Villanueva J, Martorella AJ, Lawlor K, Philip J, Fleisher M, Robbins RJ, Tempst P. Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Mol. Cell Proteomics 2006 Oct; 5(10): 1840-52
  • Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sánchez-Carbayo M, Holland EC, Cordon-Cardo C, Scher HI, Tempst P. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest. 2006 Jan; 116(1): 271-84
  • Villanueva J, Philip J, Entenberg D, Chaparro CA, Tanwar MK, Holland EC, Tempst P. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal. Chem. 2004 Mar; 76(6): 1560-70

Projectes

  • Diagnostic and Therapeutic implications of the HMGA1-RAGE signaling pathway in Triple Negative Breast Cancer. Funding Agency: Instituto de Salud Carlos III (ISCIII). 2020 – 2022.
  • El microambient immune tumoral en la patogènesi i control del linfoma de cèl.lules del mantell. Funding Agency: Fundació La Marató de TV3 2020-2022.
  • We are part of CIBERONC’s Programa de Tumores del Tracto Digestivo, as part of the group (Program ID: CB16/12/00259) led by VHIO’s Director and Head of our Gastrointestinal & Endocrine Tumors Group, Josep Tabernero (PI: Teresa Macarulla).

Notícies Relacionades

VHIO participa en una unitat de proteòmica biomèdica, liderada per l’IRB Barcelona, per avançar cap a la medicina personalitzada

L’Institut de Recerca Biomèdica, juntament amb Vall d’Hebron Institut d’Oncologia, l’Institut de Recerca contra la Leucèmia Josep Carreras, l’Institut de…

26 gen. 2022
Privacy Preferences
When you visit our website, it may store information through your browser from specific services, usually in form of cookies. Here you can change your privacy preferences. Please note that blocking some types of cookies may impact your experience on our website and the services we offer.
Privacy Policy
You have read and agreed to our privacy policy
Required